Skip to main content
SpringerLink
Log in

The Effect of Nebivolol on Left Ventricular Hypertrophy in Hypertension

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hachamovitch R, Strom JA, Sonnenblick EH, Frishman WH. Left ventricular hypertrophy in hypertension and the effects of antihypertensive drug therapy. Curr Problems Cardiol 1988;13:369–422.

    Google Scholar 

  2. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992;6:85–90.

    Google Scholar 

  3. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 studies. Am J Hypertens 1992;5:95–100.

    Google Scholar 

  4. Agabiti-Rosei E, Ambrosioni E, Dal Palu C, et al. ACE inhibitor ramipril is more effective than beta-blocker atenolol in reducing left ventricular mass in hypertension: Results of the RACE (ramipril cardioprotection evaluation) study. J Hypertens 1995;13:1325–1334.

    Google Scholar 

  5. Van de Water A, Janssens W, Van Nueten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PAJ. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. Cardiovasc Pharmacol 1988;11:552–563.

    Google Scholar 

  6. Gao Y, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991;17:964–969.

    Google Scholar 

  7. Cockroft JR, Chowienczyk PJ, Brett SA, Chen CPL-H, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an Larginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067–1071.

    Google Scholar 

  8. Janssen PM, Zeitz O, Hasenfuss G. Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol. Eur J Pharmacol 1999;366:223–232.

    Google Scholar 

  9. Van Nueten L, Taylor FR, Robertson JI. Nebivolol versus atenolol and placebo in essential hypertension: a double-blind randomized trial. J Hum Hypertens 1998;12:135–140.

    Google Scholar 

  10. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091–1095.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Chinese PLA General Hospital, Beijing, China

    Guo-Shu Liu

  2. Department of Echocardiography, Chinese PLA General Hospital, Beijing, China

    Lian Yi Wang

  3. Janssen Research Foundation, B-2340, Beerse, Belgium

    Luc Van Nueten, Leo AA Ooms, Marcel Borgers & Paul AJ Janssen

Authors
  1. Guo-Shu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lian Yi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luc Van Nueten
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leo AA Ooms
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marcel Borgers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paul AJ Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, GS., Wang, L.Y., Van Nueten, L. et al. The Effect of Nebivolol on Left Ventricular Hypertrophy in Hypertension. Cardiovasc Drugs Ther 13, 549–551 (1999). https://doi.org/10.1023/A:1007840123533

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007840123533

Search

Navigation